🔎 Trials Near Me

Home › Neurogenic Urinary Bladder › NCT06163469

Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life

Recruiting

Instillation in Neurogenic Bladders to Decrease Unplanned Healthcare Encounters

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Indwelling suprapubic catheter with insertion date at least 1 year prior to study enrollment date.
* History of urinary tract infections, treated for at least 1 positive urine culture in last 6 months

Exclusion Criteria:

* Current radiographic evidence of urolithiasis
* History of vesicoureteral reflux
* History of renal transplantation
* History of bladder augmentation
* Inability to stop use of other rUTI prophylaxis treatments for the duration of their trial enrollment
* Life expectancy of less than 12 months prior to consent.
* Known hypersensitivity or allergy to chlorhexidine.
* Women who are pregnant or breastfeeding.

About the study

The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are:

1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients. 2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life.

Patients will undergo the treatment protocol during their routine suprapubic catheter exchanges.

What is being tested

Sponsor: Yale University · Participants: 70 · Started: Apr 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06163469

Locations in the U.S.

ConnecticutYale New Haven Health, New Haven

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.